BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Bang-Andersen B, Ruhland T, Jørgensen M, Smith G, Frederiksen K, Jensen KG, Zhong H, Nielsen SM, Hogg S, Mørk A. Discovery of 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine (Lu AA21004): a novel multimodal compound for the treatment of major depressive disorder. J Med Chem. 2011;54:3206-3221. [PMID: 21486038 DOI: 10.1021/jm101459g] [Cited by in Crossref: 258] [Cited by in F6Publishing: 195] [Article Influence: 25.8] [Reference Citation Analysis]
Number Citing Articles
1 Baldwin DS, Chrones L, Florea I, Nielsen R, Nomikos GG, Palo W, Reines E. The safety and tolerability of vortioxetine: Analysis of data from randomized placebo-controlled trials and open-label extension studies. J Psychopharmacol 2016;30:242-52. [PMID: 26864543 DOI: 10.1177/0269881116628440] [Cited by in Crossref: 63] [Cited by in F6Publishing: 39] [Article Influence: 12.6] [Reference Citation Analysis]
2 Kucwaj-Brysz K, Kurczab R, Żesławska E, Lubelska A, Marć MA, Latacz G, Satała G, Nitek W, Kieć-Kononowicz K, Handzlik J. The role of aryl-topology in balancing between selective and dual 5-HT7R/5-HT1A actions of 3,5-substituted hydantoins. Medchemcomm 2018;9:1033-44. [PMID: 30108992 DOI: 10.1039/c8md00168e] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 1.7] [Reference Citation Analysis]
3 Jacobsen PL, Nomikos GG, Zhong W, Cutler AJ, Affinito J, Clayton A. Clinical implications of directly switching antidepressants in well-treated depressed patients with treatment-emergent sexual dysfunction: a comparison between vortioxetine and escitalopram. CNS Spectr 2020;25:50-63. [DOI: 10.1017/s1092852919000750] [Cited by in Crossref: 7] [Cited by in F6Publishing: 1] [Article Influence: 3.5] [Reference Citation Analysis]
4 Bronson J, Black A, Dhar M, Ellsworth B, Robert Merritt J. To Market, To Market—2013. Elsevier; 2014. pp. 437-508. [DOI: 10.1016/b978-0-12-800167-7.00027-4] [Cited by in Crossref: 5] [Article Influence: 0.7] [Reference Citation Analysis]
5 Pearce EF, Murphy JA. Vortioxetine for the treatment of depression. Ann Pharmacother 2014;48:758-65. [PMID: 24676550 DOI: 10.1177/1060028014528305] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 1.4] [Reference Citation Analysis]
6 Nissen TD, Laursen B, Viardot G, l'Hostis P, Danjou P, Sluth LB, Gram M, Bastlund JF, Christensen SR, Drewes AM. Effects of Vortioxetine and Escitalopram on Electroencephalographic Recordings – A Randomized, Crossover Trial in Healthy Males. Neuroscience 2020;424:172-81. [DOI: 10.1016/j.neuroscience.2019.09.039] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 4.0] [Reference Citation Analysis]
7 Thase ME, Mahableshwarkar AR, Dragheim M, Loft H, Vieta E. A meta-analysis of randomized, placebo-controlled trials of vortioxetine for the treatment of major depressive disorder in adults. European Neuropsychopharmacology 2016;26:979-93. [DOI: 10.1016/j.euroneuro.2016.03.007] [Cited by in Crossref: 69] [Cited by in F6Publishing: 45] [Article Influence: 13.8] [Reference Citation Analysis]
8 Garnock-Jones KP. Vortioxetine: a review of its use in major depressive disorder. CNS Drugs 2014;28:855-74. [PMID: 25145538 DOI: 10.1007/s40263-014-0195-x] [Cited by in Crossref: 29] [Cited by in F6Publishing: 15] [Article Influence: 4.8] [Reference Citation Analysis]
9 Stahl SM. Modes and nodes explain the mechanism of action of vortioxetine, a multimodal agent (MMA): actions at serotonin receptors may enhance downstream release of four pro-cognitive neurotransmitters. CNS Spectr 2015;20:515-9. [DOI: 10.1017/s1092852915000358] [Cited by in Crossref: 13] [Cited by in F6Publishing: 3] [Article Influence: 2.2] [Reference Citation Analysis]
10 Baldwin DS, Nutt DJ. On assessing potential efficacy for vortioxetine in generalized anxiety disorder. European Neuropsychopharmacology 2012;22:841-3. [DOI: 10.1016/j.euroneuro.2012.07.018] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
11 Pehrson AL, Jeyarajah T, Sanchez C. Regional distribution of serotonergic receptors: a systems neuroscience perspective on the downstream effects of the multimodal-acting antidepressant vortioxetine on excitatory and inhibitory neurotransmission. CNS Spectr 2016;21:162-83. [DOI: 10.1017/s1092852915000486] [Cited by in Crossref: 20] [Cited by in F6Publishing: 7] [Article Influence: 3.3] [Reference Citation Analysis]
12 McIntyre RS, Harrison J, Loft H, Jacobson W, Olsen CK. The Effects of Vortioxetine on Cognitive Function in Patients with Major Depressive Disorder: A Meta-Analysis of Three Randomized Controlled Trials. Int J Neuropsychopharmacol 2016;19:pyw055. [PMID: 27312740 DOI: 10.1093/ijnp/pyw055] [Cited by in Crossref: 82] [Cited by in F6Publishing: 59] [Article Influence: 16.4] [Reference Citation Analysis]
13 Simmler LD, Liechti ME. Interactions of Cathinone NPS with Human Transporters and Receptors in Transfected Cells. Curr Top Behav Neurosci 2017;32:49-72. [PMID: 27272068 DOI: 10.1007/7854_2016_20] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 3.5] [Reference Citation Analysis]
14 Baldwin DS, Loft H, Dragheim M. A randomised, double-blind, placebo controlled, duloxetine-referenced, fixed-dose study of three dosages of Lu AA21004 in acute treatment of major depressive disorder (MDD). Eur Neuropsychopharmacol. 2012;22:482-491. [PMID: 22209361 DOI: 10.1016/j.euroneuro.2011.11.008] [Cited by in Crossref: 97] [Cited by in F6Publishing: 66] [Article Influence: 9.7] [Reference Citation Analysis]
15 Yang KC, Stepanov V, Martinsson S, Ettrup A, Takano A, Knudsen GM, Halldin C, Farde L, Finnema SJ. Fenfluramine Reduces [11C]Cimbi-36 Binding to the 5-HT2A Receptor in the Nonhuman Primate Brain. Int J Neuropsychopharmacol 2017;20:683-91. [PMID: 28911007 DOI: 10.1093/ijnp/pyx051] [Cited by in Crossref: 18] [Cited by in F6Publishing: 13] [Article Influence: 6.0] [Reference Citation Analysis]
16 Boulenger JP, Loft H, Florea I. A randomized clinical study of Lu AA21004 in the prevention of relapse in patients with major depressive disorder. J Psychopharmacol. 2012;26:1408-1416. [PMID: 22495621 DOI: 10.1177/0269881112441866] [Cited by in Crossref: 74] [Cited by in F6Publishing: 51] [Article Influence: 8.2] [Reference Citation Analysis]
17 Waller JA, Nygaard SH, Li Y, du Jardin KG, Tamm JA, Abdourahman A, Elfving B, Pehrson AL, Sánchez C, Wernersson R. Neuroplasticity pathways and protein-interaction networks are modulated by vortioxetine in rodents. BMC Neurosci 2017;18:56. [PMID: 28778148 DOI: 10.1186/s12868-017-0376-x] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 1.8] [Reference Citation Analysis]
18 Rothschild AJ, Mahableshwarkar AR, Jacobsen P, Yan M, Sheehan DV. Vortioxetine (Lu AA21004) 5mg in generalized anxiety disorder: Results of an 8-week randomized, double-blind, placebo-controlled clinical trial in the United States. European Neuropsychopharmacology 2012;22:858-66. [DOI: 10.1016/j.euroneuro.2012.07.011] [Cited by in Crossref: 38] [Cited by in F6Publishing: 30] [Article Influence: 4.2] [Reference Citation Analysis]
19 Modica MN, Lacivita E, Intagliata S, Salerno L, Romeo G, Pittalà V, Leopoldo M. Structure-Activity Relationships and Therapeutic Potentials of 5-HT7 Receptor Ligands: An Update. J Med Chem 2018;61:8475-503. [PMID: 29767995 DOI: 10.1021/acs.jmedchem.7b01898] [Cited by in Crossref: 22] [Cited by in F6Publishing: 17] [Article Influence: 7.3] [Reference Citation Analysis]
20 Mahableshwarkar AR, Zajecka J, Jacobson W, Chen Y, Keefe RS. A Randomized, Placebo-Controlled, Active-Reference, Double-Blind, Flexible-Dose Study of the Efficacy of Vortioxetine on Cognitive Function in Major Depressive Disorder. Neuropsychopharmacology 2015;40:2025-37. [PMID: 25687662 DOI: 10.1038/npp.2015.52] [Cited by in Crossref: 160] [Cited by in F6Publishing: 115] [Article Influence: 26.7] [Reference Citation Analysis]
21 Waller JA, Tamm JA, Abdourahman A, Pehrson AL, Li Y, Cajina M, Sánchez C. Chronic vortioxetine treatment in rodents modulates gene expression of neurodevelopmental and plasticity markers. Eur Neuropsychopharmacol 2017;27:192-203. [PMID: 28108062 DOI: 10.1016/j.euroneuro.2016.11.014] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
22 Veldman ER, Svedberg MM, Svenningsson P, Lundberg J. Distribution and levels of 5-HT1B receptors in anterior cingulate cortex of patients with bipolar disorder, major depressive disorder and schizophrenia - An autoradiography study. Eur Neuropsychopharmacol 2017;27:504-14. [PMID: 28318898 DOI: 10.1016/j.euroneuro.2017.02.011] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
23 Witten L, Bang-andersen B, Nielsen SM, Miller S, Christoffersen CT, Stensbøl TB, Brennum LT, Arnt J. Characterization of [3H]Lu AE60157 ([3H]8-(4-methylpiperazin-1-yl)-3-phenylsulfonylquinoline) binding to 5-hydroxytryptamine6 (5-HT6) receptors in vivo. European Journal of Pharmacology 2012;676:6-11. [DOI: 10.1016/j.ejphar.2011.11.029] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
24 Okubo R, Hasegawa T, Fukuyama K, Shiroyama T, Okada M. Current Limitations and Candidate Potential of 5-HT7 Receptor Antagonism in Psychiatric Pharmacotherapy. Front Psychiatry 2021;12:623684. [PMID: 33679481 DOI: 10.3389/fpsyt.2021.623684] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
25 Oosterhof CA, El Mansari M, Blier P. Asenapine alters the activity of monoaminergic systems following its subacute and long-term administration: An in vivo electrophysiological characterization. European Neuropsychopharmacology 2015;25:531-43. [DOI: 10.1016/j.euroneuro.2015.01.006] [Cited by in Crossref: 11] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
26 Wang Y, Zhang X, Liu H, Chen H, Huang D. Nickel-catalyzed direct formation of the C–S bonds of aryl sulfides from arylsulfonyl chlorides and aryl iodides using Mn as a reducing agent. Org Chem Front 2017;4:31-6. [DOI: 10.1039/c6qo00451b] [Cited by in Crossref: 20] [Cited by in F6Publishing: 1] [Article Influence: 5.0] [Reference Citation Analysis]
27 Li Y, Abdourahman A, Tamm JA, Pehrson AL, Sánchez C, Gulinello M. Reversal of age-associated cognitive deficits is accompanied by increased plasticity-related gene expression after chronic antidepressant administration in middle-aged mice. Pharmacology Biochemistry and Behavior 2015;135:70-82. [DOI: 10.1016/j.pbb.2015.05.013] [Cited by in Crossref: 53] [Cited by in F6Publishing: 39] [Article Influence: 8.8] [Reference Citation Analysis]
28 Pitsillou E, Bresnehan SM, Kagarakis EA, Wijoyo SJ, Liang J, Hung A, Karagiannis TC. The cellular and molecular basis of major depressive disorder: towards a unified model for understanding clinical depression. Mol Biol Rep 2020;47:753-70. [PMID: 31612411 DOI: 10.1007/s11033-019-05129-3] [Cited by in Crossref: 24] [Cited by in F6Publishing: 18] [Article Influence: 12.0] [Reference Citation Analysis]
29 Bétry C, Pehrson AL, Etiévant A, Ebert B, Sánchez C, Haddjeri N. The rapid recovery of 5-HT cell firing induced by the antidepressant vortioxetine involves 5-HT3 receptor antagonism. International Journal of Neuropsychopharmacology 2013;16:1115-27. [DOI: 10.1017/s1461145712001058] [Cited by in Crossref: 42] [Cited by in F6Publishing: 16] [Article Influence: 5.3] [Reference Citation Analysis]
30 Chen G, Højer AM, Areberg J, Nomikos G. Vortioxetine: Clinical Pharmacokinetics and Drug Interactions. Clin Pharmacokinet 2018;57:673-86. [PMID: 29189941 DOI: 10.1007/s40262-017-0612-7] [Cited by in Crossref: 40] [Cited by in F6Publishing: 24] [Article Influence: 20.0] [Reference Citation Analysis]
31 Nomikos GG, Tomori D, Zhong W, Affinito J, Palo W. Efficacy, safety, and tolerability of vortioxetine for the treatment of major depressive disorder in patients aged 55 years or older. CNS Spectr 2017;22:348-62. [PMID: 27869048 DOI: 10.1017/S1092852916000626] [Cited by in Crossref: 11] [Cited by in F6Publishing: 1] [Article Influence: 2.2] [Reference Citation Analysis]
32 Jensen JB, du Jardin KG, Song D, Budac D, Smagin G, Sanchez C, Pehrson AL. Vortioxetine, but not escitalopram or duloxetine, reverses memory impairment induced by central 5-HT depletion in rats: Evidence for direct 5-HT receptor modulation. European Neuropsychopharmacology 2014;24:148-59. [DOI: 10.1016/j.euroneuro.2013.10.011] [Cited by in Crossref: 61] [Cited by in F6Publishing: 49] [Article Influence: 8.7] [Reference Citation Analysis]
33 Pandey AK, Chand S, Singh R, Kumar S, Singh KN. Iodine-Catalyzed Synthesis of 3-Arylthioindoles Employing a 1-Aryltriazene/CS2 Combination as a New Sulfenylation Source. ACS Omega 2020;5:7627-35. [PMID: 32280906 DOI: 10.1021/acsomega.0c00472] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 6.0] [Reference Citation Analysis]
34 Pehrson AL, Cremers T, Bétry C, van der Hart MG, Jørgensen L, Madsen M, Haddjeri N, Ebert B, Sanchez C. Lu AA21004, a novel multimodal antidepressant, produces regionally selective increases of multiple neurotransmitters--a rat microdialysis and electrophysiology study. Eur Neuropsychopharmacol 2013;23:133-45. [PMID: 22612991 DOI: 10.1016/j.euroneuro.2012.04.006] [Cited by in Crossref: 101] [Cited by in F6Publishing: 82] [Article Influence: 11.2] [Reference Citation Analysis]
35 Cowen P, Sherwood AC. The role of serotonin in cognitive function: evidence from recent studies and implications for understanding depression. J Psychopharmacol 2013;27:575-83. [DOI: 10.1177/0269881113482531] [Cited by in Crossref: 64] [Cited by in F6Publishing: 47] [Article Influence: 8.0] [Reference Citation Analysis]
36 Montgomery SA, Nielsen RZ, Poulsen LH, Häggström L. A randomised, double-blind study in adults with major depressive disorder with an inadequate response to a single course of selective serotonin reuptake inhibitor or serotonin-noradrenaline reuptake inhibitor treatment switched to vortioxetine or agomelatine. Hum Psychopharmacol 2014;29:470-82. [PMID: 25087600 DOI: 10.1002/hup.2424] [Cited by in Crossref: 69] [Cited by in F6Publishing: 43] [Article Influence: 11.5] [Reference Citation Analysis]
37 Andersen J, Ladefoged LK, Wang D, Kristensen TN, Bang-Andersen B, Kristensen AS, Schiøtt B, Strømgaard K. Binding of the multimodal antidepressant drug vortioxetine to the human serotonin transporter. ACS Chem Neurosci 2015;6:1892-900. [PMID: 26389667 DOI: 10.1021/acschemneuro.5b00225] [Cited by in Crossref: 21] [Cited by in F6Publishing: 15] [Article Influence: 3.5] [Reference Citation Analysis]
38 Bobo W, Kelliny M, Croarkin P, Moore K. Profile of vortioxetine in the treatment of major depressive disorder: an overview of the primary and secondary literature. TCRM. [DOI: 10.2147/tcrm.s55313] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
39 Gomółka A, Ciesielska A, Wróbel MZ, Chodkowski A, Kleps J, Dawidowski M, Siwek A, Wolak M, Stachowicz K, Sławińska A, Nowak G, Satała G, Bojarski AJ, Belka M, Ulenberg S, Bączek T, Skowronek P, Turło J, Herold F. Novel 4-aryl-pyrido[1,2-c]pyrimidines with dual SSRI and 5-HT(1A) activity. Part 5. Eur J Med Chem 2015;98:221-36. [PMID: 26043160 DOI: 10.1016/j.ejmech.2015.05.003] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
40 Nishimura A, Aritomi Y, Sasai K, Kitagawa T, Mahableshwarkar AR. Randomized, double-blind, placebo-controlled 8-week trial of the efficacy, safety, and tolerability of 5, 10, and 20 mg/day vortioxetine in adults with major depressive disorder: Vortioxetine for major depression. Psychiatry Clin Neurosci 2018;72:64-72. [DOI: 10.1111/pcn.12565] [Cited by in Crossref: 11] [Cited by in F6Publishing: 5] [Article Influence: 2.8] [Reference Citation Analysis]
41 Li Y, Raaby KF, Sánchez C, Gulinello M. Serotonergic receptor mechanisms underlying antidepressant-like action in the progesterone withdrawal model of hormonally induced depression in rats. Behav Brain Res 2013;256:520-8. [PMID: 24016840 DOI: 10.1016/j.bbr.2013.09.002] [Cited by in Crossref: 40] [Cited by in F6Publishing: 26] [Article Influence: 5.0] [Reference Citation Analysis]
42 Shaquiquzzaman M, Verma G, Marella A, Akhter M, Akhtar W, Khan MF, Tasneem S, Alam MM. Piperazine scaffold: A remarkable tool in generation of diverse pharmacological agents. Eur J Med Chem 2015;102:487-529. [PMID: 26310894 DOI: 10.1016/j.ejmech.2015.07.026] [Cited by in Crossref: 84] [Cited by in F6Publishing: 45] [Article Influence: 14.0] [Reference Citation Analysis]
43 Areberg J, Luntang-jensen M, Søgaard B, Nilausen DØ. Occupancy of the Serotonin Transporter after Administration of Lu AA21004 and its Relation to Plasma Concentration in Healthy Subjects: Lu AA21004 SERT OCCUPANCY. Basic & Clinical Pharmacology & Toxicology 2012;110:401-4. [DOI: 10.1111/j.1742-7843.2011.00810.x] [Cited by in Crossref: 47] [Cited by in F6Publishing: 31] [Article Influence: 4.7] [Reference Citation Analysis]
44 Baune BT, Sluth LB, Olsen CK. The effects of vortioxetine on cognitive performance in working patients with major depressive disorder: A short-term, randomized, double-blind, exploratory study. J Affect Disord 2018;229:421-8. [PMID: 29331703 DOI: 10.1016/j.jad.2017.12.056] [Cited by in Crossref: 21] [Cited by in F6Publishing: 14] [Article Influence: 5.3] [Reference Citation Analysis]
45 McIntyre RS, Lophaven S, Olsen CK. A randomized, double-blind, placebo-controlled study of vortioxetine on cognitive function in depressed adults. Int J Neuropsychopharmacol 2014;17:1557-67. [PMID: 24787143 DOI: 10.1017/S1461145714000546] [Cited by in Crossref: 205] [Cited by in F6Publishing: 65] [Article Influence: 29.3] [Reference Citation Analysis]
46 Gupta D, Prabhakar V, Radhakrishnan M. 5HT3 receptors: Target for new antidepressant drugs. Neurosci Biobehav Rev 2016;64:311-25. [PMID: 26976353 DOI: 10.1016/j.neubiorev.2016.03.001] [Cited by in Crossref: 25] [Cited by in F6Publishing: 14] [Article Influence: 5.0] [Reference Citation Analysis]
47 Stenkrona P, Halldin C, Lundberg J. 5-HTT and 5-HT1A receptor occupancy of the novel substance vortioxetine (Lu AA21004). A PET study in control subjects. European Neuropsychopharmacology 2013;23:1190-8. [DOI: 10.1016/j.euroneuro.2013.01.002] [Cited by in Crossref: 51] [Cited by in F6Publishing: 27] [Article Influence: 6.4] [Reference Citation Analysis]
48 Okada M, Matsumoto R, Yamamoto Y, Fukuyama K. Effects of Subchronic Administrations of Vortioxetine, Lurasidone, and Escitalopram on Thalamocortical Glutamatergic Transmission Associated with Serotonin 5-HT7 Receptor. Int J Mol Sci 2021;22:1351. [PMID: 33572981 DOI: 10.3390/ijms22031351] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
49 Vieta E, Sluth LB, Olsen CK. The effects of vortioxetine on cognitive dysfunction in patients with inadequate response to current antidepressants in major depressive disorder: A short-term, randomized, double-blind, exploratory study versus escitalopram. J Affect Disord 2018;227:803-9. [PMID: 29673132 DOI: 10.1016/j.jad.2017.11.053] [Cited by in Crossref: 23] [Cited by in F6Publishing: 13] [Article Influence: 5.8] [Reference Citation Analysis]
50 Richelson E. Multi-modality: a new approach for the treatment of major depressive disorder. Int J Neuropsychopharmacol 2013;16:1433-42. [PMID: 23363735 DOI: 10.1017/S1461145712001605] [Cited by in Crossref: 25] [Cited by in F6Publishing: 8] [Article Influence: 3.1] [Reference Citation Analysis]
51 David DJ, Tritschler L, Guilloux JP, Gardier AM, Sanchez C, Gaillard R. [Pharmacological properties of vortioxetine and its pre-clinical consequences]. Encephale 2016;42:1S12-23. [PMID: 26879252 DOI: 10.1016/S0013-7006(16)30015-X] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
52 Zeppelin T, Ladefoged LK, Sinning S, Schiøtt B. Substrate and inhibitor binding to the serotonin transporter: Insights from computational, crystallographic, and functional studies. Neuropharmacology 2019;161:107548. [PMID: 30807752 DOI: 10.1016/j.neuropharm.2019.02.030] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
53 Raymer B, Bhattacharya SK. Lead-like Drugs: A Perspective: Miniperspective. J Med Chem 2018;61:10375-84. [DOI: 10.1021/acs.jmedchem.8b00407] [Cited by in Crossref: 24] [Cited by in F6Publishing: 17] [Article Influence: 8.0] [Reference Citation Analysis]
54 Cuboni S, Hausch F. Snapshot of antidepressants at work: the structure of neurotransmitter transporter proteins. Angew Chem Int Ed Engl 2014;53:5008-9. [PMID: 24729171 DOI: 10.1002/anie.201310567] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
55 Jain R, Mahableshwarkar AR, Jacobsen PL, Chen Y, Thase ME. A randomized, double-blind, placebo-controlled 6-wk trial of the efficacy and tolerability of 5 mg vortioxetine in adults with major depressive disorder. Int J Neuropsychopharmacol. 2013;16:313-321. [PMID: 22963932 DOI: 10.1017/s1461145712000727] [Cited by in Crossref: 77] [Cited by in F6Publishing: 23] [Article Influence: 8.6] [Reference Citation Analysis]
56 Millan MJ, Rivet J, Gobert A. The frontal cortex as a network hub controlling mood and cognition: Probing its neurochemical substrates for improved therapy of psychiatric and neurological disorders. J Psychopharmacol 2016;30:1099-128. [DOI: 10.1177/0269881116672342] [Cited by in Crossref: 26] [Cited by in F6Publishing: 23] [Article Influence: 5.2] [Reference Citation Analysis]
57 Kristensen AS, Andersen J, Jørgensen TN, Sørensen L, Eriksen J, Loland CJ, Strømgaard K, Gether U. SLC6 neurotransmitter transporters: structure, function, and regulation. Pharmacol Rev 2011;63:585-640. [PMID: 21752877 DOI: 10.1124/pr.108.000869] [Cited by in Crossref: 509] [Cited by in F6Publishing: 387] [Article Influence: 50.9] [Reference Citation Analysis]
58 Sagud M, Nikolac Perkovic M, Vuksan-cusa B, Maravic A, Svob Strac D, Mihaljevic Peles A, Zivkovic M, Kusevic Z, Pivac N. A prospective, longitudinal study of platelet serotonin and plasma brain-derived neurotrophic factor concentrations in major depression: effects of vortioxetine treatment. Psychopharmacology 2016;233:3259-67. [DOI: 10.1007/s00213-016-4364-0] [Cited by in Crossref: 18] [Cited by in F6Publishing: 14] [Article Influence: 3.6] [Reference Citation Analysis]
59 Stahl SM. Modes and nodes explain the mechanism of action of vortioxetine, a multimodal agent (MMA): enhancing serotonin release by combining serotonin (5HT) transporter inhibition with actions at 5HT receptors (5HT1A, 5HT1B, 5HT1D, 5HT7 receptors). CNS Spectr 2015;20:93-7. [PMID: 25831967 DOI: 10.1017/S1092852915000139] [Cited by in Crossref: 30] [Cited by in F6Publishing: 12] [Article Influence: 5.0] [Reference Citation Analysis]
60 Smagin GN, Song D, Budac DP, Waller JA, Li Y, Pehrson AL, Sánchez C. Histamine may contribute to vortioxetine's procognitive effects; possibly through an orexigenic mechanism. Progress in Neuro-Psychopharmacology and Biological Psychiatry 2016;68:25-30. [DOI: 10.1016/j.pnpbp.2016.03.001] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.4] [Reference Citation Analysis]
61 Sartori SB, Singewald N. Novel pharmacological targets in drug development for the treatment of anxiety and anxiety-related disorders. Pharmacol Ther 2019;204:107402. [PMID: 31470029 DOI: 10.1016/j.pharmthera.2019.107402] [Cited by in Crossref: 44] [Cited by in F6Publishing: 23] [Article Influence: 22.0] [Reference Citation Analysis]
62 Mørk A, Pehrson A, Brennum LT, Nielsen SM, Zhong H, Lassen AB, Miller S, Westrich L, Boyle NJ, Sánchez C. Pharmacological effects of Lu AA21004: a novel multimodal compound for the treatment of major depressive disorder. J Pharmacol Exp Ther. 2012;340:666-675. [PMID: 22171087 DOI: 10.1124/jpet.111.189068] [Cited by in Crossref: 181] [Cited by in F6Publishing: 147] [Article Influence: 18.1] [Reference Citation Analysis]
63 Chakroborty S, Geisbush TR, Dale E, Pehrson AL, Sánchez C, West AR. Impact of Vortioxetine on Synaptic Integration in Prefrontal-Subcortical Circuits: Comparisons with Escitalopram. Front Pharmacol 2017;8:764. [PMID: 29123483 DOI: 10.3389/fphar.2017.00764] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
64 Katona CL, Katona CP. New generation multi-modal antidepressants: focus on vortioxetine for major depressive disorder. Neuropsychiatr Dis Treat 2014;10:349-54. [PMID: 24570588 DOI: 10.2147/NDT.S39544] [Cited by in Crossref: 25] [Cited by in F6Publishing: 6] [Article Influence: 3.6] [Reference Citation Analysis]
65 Florea I, Loft H, Danchenko N, Rive B, Brignone M, Merikle E, Jacobsen PL, Sheehan DV. The effect of vortioxetine on overall patient functioning in patients with major depressive disorder. Brain Behav 2017;7:e00622. [PMID: 28293465 DOI: 10.1002/brb3.622] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
66 Alam MY, Jacobsen PL, Chen Y, Serenko M, Mahableshwarkar AR. Safety, tolerability, and efficacy of vortioxetine (Lu AA21004) in major depressive disorder: results of an open-label, flexible-dose, 52-week extension study. Int Clin Psychopharmacol. 2014;29:36-44. [PMID: 24169027 DOI: 10.1097/yic.0000000000000010] [Cited by in Crossref: 39] [Cited by in F6Publishing: 16] [Article Influence: 5.6] [Reference Citation Analysis]
67 Leiser SC, Iglesias-Bregna D, Westrich L, Pehrson AL, Sanchez C. Differentiated effects of the multimodal antidepressant vortioxetine on sleep architecture: Part 2, pharmacological interactions in rodents suggest a role of serotonin-3 receptor antagonism. J Psychopharmacol 2015;29:1092-105. [PMID: 26174134 DOI: 10.1177/0269881115592347] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
68 Chen G, Zhang W, Serenko M. Lack of effect of multiple doses of vortioxetine on the pharmacokinetics and pharmacodynamics of aspirin and warfarin. The Journal of Clinical Pharmacology 2015;55:671-9. [DOI: 10.1002/jcph.456] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 2.7] [Reference Citation Analysis]
69 Findling RL, Robb AS, DelBello M, Huss M, McNamara N, Sarkis E, Scheffer R, Poulsen LH, Chen G, Lemming OM, Areberg J, Auby P. Pharmacokinetics and Safety of Vortioxetine in Pediatric Patients. J Child Adolesc Psychopharmacol 2017;27:526-34. [PMID: 28333546 DOI: 10.1089/cap.2016.0155] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 1.8] [Reference Citation Analysis]
70 Zohar J, Nutt DJ, Kupfer DJ, Moller H, Yamawaki S, Spedding M, Stahl SM. A proposal for an updated neuropsychopharmacological nomenclature. European Neuropsychopharmacology 2014;24:1005-14. [DOI: 10.1016/j.euroneuro.2013.08.004] [Cited by in Crossref: 61] [Cited by in F6Publishing: 32] [Article Influence: 8.7] [Reference Citation Analysis]
71 Taciak PP, Lysenko N, Mazurek AP. Drugs which influence serotonin transporter and serotonergic receptors: Pharmacological and clinical properties in the treatment of depression. Pharmacological Reports 2018;70:37-46. [DOI: 10.1016/j.pharep.2017.07.011] [Cited by in Crossref: 25] [Cited by in F6Publishing: 18] [Article Influence: 8.3] [Reference Citation Analysis]
72 He H, Wang W, Lyu J, Zheng J, Guo L, An X, Fan Y, Ma X. Efficacy and tolerability of different doses of three new antidepressants for treating major depressive disorder: A PRISMA-compliant meta-analysis. Journal of Psychiatric Research 2018;96:247-59. [DOI: 10.1016/j.jpsychires.2017.10.018] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
73 Uldam HK, Juhl M, Pedersen H, Dalgaard L. Biosynthesis and Identification of an N -Oxide/ N -Glucuronide Metabolite and First Synthesis of an N-O -Glucuronide Metabolite of Lu AA21004. Drug Metab Dispos 2011;39:2264-74. [DOI: 10.1124/dmd.111.040428] [Cited by in Crossref: 24] [Cited by in F6Publishing: 18] [Article Influence: 2.4] [Reference Citation Analysis]
74 Bawa P, Pradeep P, Kumar P, Choonara YE, Modi G, Pillay V. Multi-target therapeutics for neuropsychiatric and neurodegenerative disorders. Drug Discov Today 2016;21:1886-914. [PMID: 27506871 DOI: 10.1016/j.drudis.2016.08.001] [Cited by in Crossref: 24] [Cited by in F6Publishing: 21] [Article Influence: 4.8] [Reference Citation Analysis]
75 Guilloux JP, Mendez-David I, Pehrson A, Guiard BP, Repérant C, Orvoën S, Gardier AM, Hen R, Ebert B, Miller S, Sanchez C, David DJ. Antidepressant and anxiolytic potential of the multimodal antidepressant vortioxetine (Lu AA21004) assessed by behavioural and neurogenesis outcomes in mice. Neuropharmacology 2013;73:147-59. [PMID: 23721744 DOI: 10.1016/j.neuropharm.2013.05.014] [Cited by in Crossref: 80] [Cited by in F6Publishing: 62] [Article Influence: 10.0] [Reference Citation Analysis]
76 Chen G, Nomikos GG, Affinito J, Jacobson W, Zhao Z, Wang S, Xie J. Effects of Intrinsic Factors on the Clinical Pharmacokinetics of Vortioxetine. Clinical Pharmacology in Drug Development 2018;7:880-8. [DOI: 10.1002/cpdd.577] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
77 Fiorillo A, Carpiniello B, De Giorgi S, La Pia S, Maina G, Sampogna G, Spina E, Tortorella A, Vita A. Assessment and Management of Cognitive and Psychosocial Dysfunctions in Patients With Major Depressive Disorder: A Clinical Review. Front Psychiatry 2018;9:493. [PMID: 30364225 DOI: 10.3389/fpsyt.2018.00493] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
78 Severinsen K, Kraft JF, Koldsø H, Vinberg KA, Rothman RB, Partilla JS, Wiborg O, Blough B, Schiøtt B, Sinning S. Binding of the amphetamine-like 1-phenyl-piperazine to monoamine transporters. ACS Chem Neurosci 2012;3:693-705. [PMID: 23019496 DOI: 10.1021/cn300040f] [Cited by in Crossref: 22] [Cited by in F6Publishing: 19] [Article Influence: 2.4] [Reference Citation Analysis]
79 Mills NT, Sampson E, Fourrier C, Baune BT. Clinical Switching Strategies of Various Antidepressants to Vortioxetine in the PREDDICT Trial. Int J Neuropsychopharmacol 2021;24:314-21. [PMID: 33269395 DOI: 10.1093/ijnp/pyaa092] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
80 Hamon M, Blier P. Monoamine neurocircuitry in depression and strategies for new treatments. Prog Neuropsychopharmacol Biol Psychiatry 2013;45:54-63. [PMID: 23602950 DOI: 10.1016/j.pnpbp.2013.04.009] [Cited by in Crossref: 268] [Cited by in F6Publishing: 203] [Article Influence: 33.5] [Reference Citation Analysis]
81 Hillhouse TM, Porter JH. A brief history of the development of antidepressant drugs: from monoamines to glutamate. Exp Clin Psychopharmacol 2015;23:1-21. [PMID: 25643025 DOI: 10.1037/a0038550] [Cited by in Crossref: 172] [Cited by in F6Publishing: 109] [Article Influence: 28.7] [Reference Citation Analysis]
82 Sowa-kućma M, Pańczyszyn-trzewik P, Misztak P, Jaeschke RR, Sendek K, Styczeń K, Datka W, Koperny M. Vortioxetine: A review of the pharmacology and clinical profile of the novel antidepressant. Pharmacological Reports 2017;69:595-601. [DOI: 10.1016/j.pharep.2017.01.030] [Cited by in Crossref: 33] [Cited by in F6Publishing: 23] [Article Influence: 8.3] [Reference Citation Analysis]
83 du Jardin KG, Jensen JB, Sanchez C, Pehrson AL. Vortioxetine dose-dependently reverses 5-HT depletion-induced deficits in spatial working and object recognition memory: A potential role for 5-HT1A receptor agonism and 5-HT3 receptor antagonism. European Neuropsychopharmacology 2014;24:160-71. [DOI: 10.1016/j.euroneuro.2013.07.001] [Cited by in Crossref: 78] [Cited by in F6Publishing: 62] [Article Influence: 11.1] [Reference Citation Analysis]
84 Vieta E, Loft H, Florea I. Effectiveness of long-term vortioxetine treatment of patients with major depressive disorder. European Neuropsychopharmacology 2017;27:877-84. [DOI: 10.1016/j.euroneuro.2017.06.012] [Cited by in Crossref: 15] [Cited by in F6Publishing: 6] [Article Influence: 3.8] [Reference Citation Analysis]
85 Pehrson AL, Sanchez C. Serotonergic modulation of glutamate neurotransmission as a strategy for treating depression and cognitive dysfunction. CNS Spectr 2014;19:121-33. [PMID: 23903233 DOI: 10.1017/S1092852913000540] [Cited by in Crossref: 91] [Cited by in F6Publishing: 30] [Article Influence: 11.4] [Reference Citation Analysis]
86 Sharma H, Santra S, Dutta A. Triple reuptake inhibitors as potential next-generation antidepressants: a new hope? Future Med Chem 2015;7:2385-406. [PMID: 26619226 DOI: 10.4155/fmc.15.134] [Cited by in Crossref: 20] [Cited by in F6Publishing: 14] [Article Influence: 3.3] [Reference Citation Analysis]
87 Zajdel P, Masurier N, Canale V, Verdie P, Amblard M, Pawłowski M, Martinez J, Subra G. The pipecolic linker—an acid-labile handle for derivatization of secondary amines on a solid-support. Part 3. Tetrahedron Letters 2013;54:998-1002. [DOI: 10.1016/j.tetlet.2012.12.036] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
88 Bucki A, Marcinkowska M, Śniecikowska J, Więckowski K, Pawłowski M, Głuch-Lutwin M, Gryboś A, Siwek A, Pytka K, Jastrzębska-Więsek M, Partyka A, Wesołowska A, Mierzejewski P, Kołaczkowski M. Novel 3-(1,2,3,6-Tetrahydropyridin-4-yl)-1H-indole-Based Multifunctional Ligands with Antipsychotic-Like, Mood-Modulating, and Procognitive Activity. J Med Chem 2017;60:7483-501. [PMID: 28763213 DOI: 10.1021/acs.jmedchem.7b00839] [Cited by in Crossref: 16] [Cited by in F6Publishing: 10] [Article Influence: 4.0] [Reference Citation Analysis]
89 Okada M, Okubo R, Fukuyama K. Vortioxetine Subchronically Activates Serotonergic Transmission via Desensitization of Serotonin 5-HT1A Receptor with 5-HT3 Receptor Inhibition in Rats. Int J Mol Sci 2019;20:E6235. [PMID: 31835640 DOI: 10.3390/ijms20246235] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 7.0] [Reference Citation Analysis]
90 Al-Sukhni M, Maruschak NA, McIntyre RS. Vortioxetine : a review of efficacy, safety and tolerability with a focus on cognitive symptoms in major depressive disorder. Expert Opin Drug Saf 2015;14:1291-304. [PMID: 26022537 DOI: 10.1517/14740338.2015.1046836] [Cited by in Crossref: 35] [Cited by in F6Publishing: 20] [Article Influence: 5.8] [Reference Citation Analysis]
91 Bétry C, Etiévant A, Pehrson A, Sánchez C, Haddjeri N. Effect of the multimodal acting antidepressant vortioxetine on rat hippocampal plasticity and recognition memory. Progress in Neuro-Psychopharmacology and Biological Psychiatry 2015;58:38-46. [DOI: 10.1016/j.pnpbp.2014.12.002] [Cited by in Crossref: 34] [Cited by in F6Publishing: 25] [Article Influence: 5.7] [Reference Citation Analysis]
92 Nakayama H, Umeda S, Nibuya M, Terao T, Nisijima K, Nomura S. Two cases of mild serotonin toxicity via 5-hydroxytryptamine 1A receptor stimulation. Neuropsychiatr Dis Treat 2014;10:283-7. [PMID: 24627634 DOI: 10.2147/NDT.S58714] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
93 Sun Q, Wang J, Li Y, Zhuang J, Zhang Q, Sun X, Sun D. Synthesis and evaluation of cytotoxic activities of artemisinin derivatives. Chem Biol Drug Des 2017;90:1019-28. [DOI: 10.1111/cbdd.13016] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
94 Murrough JW, Yaqubi S, Sayed S, Charney DS. Emerging drugs for the treatment of anxiety. Expert Opin Emerg Drugs 2015;20:393-406. [PMID: 26012843 DOI: 10.1517/14728214.2015.1049996] [Cited by in Crossref: 54] [Cited by in F6Publishing: 26] [Article Influence: 9.0] [Reference Citation Analysis]
95 Mørk A, Montezinho LP, Miller S, Trippodi-Murphy C, Plath N, Li Y, Gulinello M, Sanchez C. Vortioxetine (Lu AA21004), a novel multimodal antidepressant, enhances memory in rats. Pharmacol Biochem Behav 2013;105:41-50. [PMID: 23380522 DOI: 10.1016/j.pbb.2013.01.019] [Cited by in Crossref: 100] [Cited by in F6Publishing: 77] [Article Influence: 12.5] [Reference Citation Analysis]
96 Pae CU, Wang SM, Han C, Lee SJ, Patkar AA, Masand PS, Serretti A. Vortioxetine, a multimodal antidepressant for generalized anxiety disorder: a systematic review and meta-analysis. J Psychiatr Res 2015;64:88-98. [PMID: 25851751 DOI: 10.1016/j.jpsychires.2015.02.017] [Cited by in Crossref: 31] [Cited by in F6Publishing: 22] [Article Influence: 5.2] [Reference Citation Analysis]
97 Chen G, Nomikos GG, Affinito J, Zhao Z. Lack of Effect of Vortioxetine on the Pharmacokinetics and Pharmacodynamics of Ethanol, Diazepam, and Lithium. Clin Pharmacokinet 2016;55:1115-27. [PMID: 27048210 DOI: 10.1007/s40262-016-0389-0] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 2.3] [Reference Citation Analysis]
98 Salagre E, Grande I, Solé B, Sanchez-Moreno J, Vieta E. Vortioxetine: A new alternative for the treatment of major depressive disorder. Rev Psiquiatr Salud Ment (Engl Ed) 2018;11:48-59. [PMID: 28800937 DOI: 10.1016/j.rpsm.2017.06.006] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 4.0] [Reference Citation Analysis]
99 Jacobsen PL, Mahableshwarkar AR, Palo WA, Chen Y, Dragheim M, Clayton AH. Treatment-emergent sexual dysfunction in randomized trials of vortioxetine for major depressive disorder or generalized anxiety disorder: a pooled analysis. CNS Spectr 2016;21:367-78. [PMID: 26575433 DOI: 10.1017/S1092852915000553] [Cited by in Crossref: 28] [Cited by in F6Publishing: 7] [Article Influence: 4.7] [Reference Citation Analysis]
100 Dale E, Bang-andersen B, Sánchez C. Emerging mechanisms and treatments for depression beyond SSRIs and SNRIs. Biochemical Pharmacology 2015;95:81-97. [DOI: 10.1016/j.bcp.2015.03.011] [Cited by in Crossref: 123] [Cited by in F6Publishing: 96] [Article Influence: 20.5] [Reference Citation Analysis]
101 Bortolato B, Miskowiak KW, Köhler CA, Maes M, Fernandes BS, Berk M, Carvalho AF. Cognitive remission: a novel objective for the treatment of major depression? BMC Med 2016;14:9. [PMID: 26801406 DOI: 10.1186/s12916-016-0560-3] [Cited by in Crossref: 104] [Cited by in F6Publishing: 66] [Article Influence: 20.8] [Reference Citation Analysis]
102 Jacobsen P, Zhong W, Xu R, Nomikos G. A novel study design for investigating relapse prevention in major depressive disorder: Preliminary data from the open-label period of a phase 4 vortioxetine study. J Affect Disord 2020;266:173-81. [PMID: 32056873 DOI: 10.1016/j.jad.2020.01.090] [Reference Citation Analysis]
103 Gonda X, Sharma SR, Tarazi FI. Vortioxetine: a novel antidepressant for the treatment of major depressive disorder. Expert Opinion on Drug Discovery 2018;14:81-9. [DOI: 10.1080/17460441.2019.1546691] [Cited by in Crossref: 24] [Cited by in F6Publishing: 15] [Article Influence: 8.0] [Reference Citation Analysis]
104 Roman MW, Wilkinson SM. Vortioxetine (Brintellix ® ) and Levomilnacipran (Fetzima ® ): The Two Newest Additions to the Antidepressant Formulary. Issues in Mental Health Nursing 2014;35:972-4. [DOI: 10.3109/01612840.2014.955155] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
105 Yi Y, Ren G, Zheng M, Zhao D, Li N, Chen X, Lu Y. Simultaneous determination of deuterated vortioxetine and its major metabolite in human plasma by UPLC-MS/MS and application to a pharmacokinetic study in healthy volunteers. Journal of Chromatography B 2020;1138:121955. [DOI: 10.1016/j.jchromb.2019.121955] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
106 Zajdel P, Marciniec K, Maślankiewicz A, Grychowska K, Satała G, Duszyńska B, Lenda T, Siwek A, Nowak G, Partyka A, Wróbel D, Jastrzębska-więsek M, Bojarski AJ, Wesołowska A, Pawłowski M. Antidepressant and antipsychotic activity of new quinoline- and isoquinoline-sulfonamide analogs of aripiprazole targeting serotonin 5-HT1A/5-HT2A/5-HT7 and dopamine D2/D3 receptors. European Journal of Medicinal Chemistry 2013;60:42-50. [DOI: 10.1016/j.ejmech.2012.11.042] [Cited by in Crossref: 53] [Cited by in F6Publishing: 27] [Article Influence: 6.6] [Reference Citation Analysis]
107 Wilson S, Højer AM, Buchberg J, Areberg J, Nutt DJ. Differentiated effects of the multimodal antidepressant vortioxetine on sleep architecture: Part 1, a pharmacokinetic/pharmacodynamic comparison with paroxetine in healthy men. J Psychopharmacol 2015;29:1085-91. [PMID: 26253622 DOI: 10.1177/0269881115599387] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 2.7] [Reference Citation Analysis]
108 Ding HX, Leverett CA, Kyne RE, Liu KK, Fink SJ, Flick AC, O’donnell CJ. Synthetic approaches to the 2013 new drugs. Bioorganic & Medicinal Chemistry 2015;23:1895-922. [DOI: 10.1016/j.bmc.2015.02.056] [Cited by in Crossref: 43] [Cited by in F6Publishing: 20] [Article Influence: 7.2] [Reference Citation Analysis]
109 Stahl SM. Modes and nodes explain the mechanism of action of vortioxetine, a multimodal agent (MMA): modifying serotonin's downstream effects on glutamate and GABA (gamma amino butyric acid) release. CNS Spectr 2015;20:331-6. [PMID: 26062900 DOI: 10.1017/S1092852915000334] [Cited by in Crossref: 14] [Cited by in F6Publishing: 3] [Article Influence: 2.3] [Reference Citation Analysis]
110 Witt NA, Lee B, Ghent K, Zhang WQ, Pehrson AL, Sánchez C, Gould GG. Vortioxetine Reduces Marble Burying but Only Transiently Enhances Social Interaction Preference in Adult Male BTBR T + Itpr3 tf /J Mice. ACS Chem Neurosci 2019;10:4319-27. [DOI: 10.1021/acschemneuro.9b00386] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
111 Mahableshwarkar AR, Jacobsen PL, Chen Y, Serenko M, Trivedi MH. A randomized, double-blind, duloxetine-referenced study comparing efficacy and tolerability of 2 fixed doses of vortioxetine in the acute treatment of adults with MDD. Psychopharmacology (Berl) 2015;232:2061-70. [PMID: 25575488 DOI: 10.1007/s00213-014-3839-0] [Cited by in Crossref: 56] [Cited by in F6Publishing: 37] [Article Influence: 9.3] [Reference Citation Analysis]
112 Deardorff WJ, Grossberg GT. A review of the clinical efficacy, safety and tolerability of the antidepressants vilazodone, levomilnacipran and vortioxetine. Expert Opin Pharmacother 2014;15:2525-42. [PMID: 25224953 DOI: 10.1517/14656566.2014.960842] [Cited by in Crossref: 27] [Cited by in F6Publishing: 16] [Article Influence: 3.9] [Reference Citation Analysis]
113 Areberg J, Petersen KB, Chen G, Naik H. Population pharmacokinetic meta-analysis of vortioxetine in healthy individuals. Basic Clin Pharmacol Toxicol 2014;115:552-9. [PMID: 24766668 DOI: 10.1111/bcpt.12256] [Cited by in Crossref: 27] [Cited by in F6Publishing: 20] [Article Influence: 3.9] [Reference Citation Analysis]
114 El Mansari M, Lecours M, Blier P. Effects of acute and sustained administration of vortioxetine on the serotonin system in the hippocampus: electrophysiological studies in the rat brain. Psychopharmacology (Berl) 2015;232:2343-52. [PMID: 25665528 DOI: 10.1007/s00213-015-3870-9] [Cited by in Crossref: 24] [Cited by in F6Publishing: 15] [Article Influence: 4.0] [Reference Citation Analysis]
115 Singh R, Allam BK, Singh N, Kumari K, Singh SK, Singh KN. Nickel-Catalyzed CS Bond Formation: Synthesis of Aryl Sulfides from Arylsulfonyl Hydrazides and Boronic Acids. Adv Synth Catal 2015;357:1181-6. [DOI: 10.1002/adsc.201400983] [Cited by in Crossref: 45] [Cited by in F6Publishing: 21] [Article Influence: 7.5] [Reference Citation Analysis]
116 Topiol S. Current and Future Challenges in GPCR Drug Discovery. Methods Mol Biol 2018;1705:1-21. [PMID: 29188556 DOI: 10.1007/978-1-4939-7465-8_1] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 3.7] [Reference Citation Analysis]
117 Sharp AM, Lertphinyowong S, Yee SS, Paredes D, Gelfond J, Johnson-Pais TL, Leach RJ, Liss M, Risinger AL, Sullivan AC, Thompson IM, Morilak DA. Vortioxetine reverses medial prefrontal cortex-mediated cognitive deficits in male rats induced by castration as a model of androgen deprivation therapy for prostate cancer. Psychopharmacology (Berl) 2019;236:3183-95. [PMID: 31139875 DOI: 10.1007/s00213-019-05274-4] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
118 Qu SY, Li XY, Heng X, Qi YY, Ge PY, Ni SJ, Yao ZY, Guo R, Yang NY, Cao Y, Zhang QC, Zhu HX. Analysis of Antidepressant Activity of Huang-Lian Jie-Du Decoction Through Network Pharmacology and Metabolomics. Front Pharmacol 2021;12:619288. [PMID: 33746756 DOI: 10.3389/fphar.2021.619288] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
119 Dale E, Grunnet M, Pehrson AL, Frederiksen K, Larsen PH, Nielsen J, Stensbøl TB, Ebert B, Yin H, Lu D, Liu H, Jensen TN, Yang CR, Sanchez C. The multimodal antidepressant vortioxetine may facilitate pyramidal cell firing by inhibition of 5-HT3 receptor expressing interneurons: An in vitro study in rat hippocampus slices. Brain Res 2018;1689:1-11. [PMID: 29274875 DOI: 10.1016/j.brainres.2017.12.025] [Cited by in Crossref: 13] [Cited by in F6Publishing: 8] [Article Influence: 3.3] [Reference Citation Analysis]
120 Ladefoged LK, Munro L, Pedersen AJ, Lummis SCR, Bang-andersen B, Balle T, Schiøtt B, Kristensen AS. Modeling and Mutational Analysis of the Binding Mode for the Multimodal Antidepressant Drug Vortioxetine to the Human 5-HT 3A Receptor. Mol Pharmacol 2018;94:1421-34. [DOI: 10.1124/mol.118.113530] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
121 Wallace A, Pehrson AL, Sánchez C, Morilak DA. Vortioxetine restores reversal learning impaired by 5-HT depletion or chronic intermittent cold stress in rats. Int J Neuropsychopharmacol 2014;17:1695-706. [PMID: 24852131 DOI: 10.1017/S1461145714000571] [Cited by in Crossref: 72] [Cited by in F6Publishing: 26] [Article Influence: 10.3] [Reference Citation Analysis]
122 Stahl SM. Modes and nodes explain the mechanism of action of vortioxetine, a multimodal agent (MMA): blocking 5HT3 receptors enhances release of serotonin, norepinephrine, and acetylcholine. CNS Spectr 2015;20:455-9. [DOI: 10.1017/s1092852915000346] [Cited by in Crossref: 15] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
123 Chu X, Xie T, Wang Y, Li X, Rao W, Xu H, Shen Z. Synthesis of di(hetero)aryl sulfides by defluorinative sulfenylation of polyfluoroalkyl ketones with sodium sulfinates or arylsulfonyl chlorides. Chem Commun 2020;56:8699-702. [DOI: 10.1039/d0cc03303k] [Cited by in Crossref: 11] [Article Influence: 11.0] [Reference Citation Analysis]
124 Hvenegaard MG, Bang-andersen B, Pedersen H, Jørgensen M, Püschl A, Dalgaard L. Identification of the Cytochrome P450 and Other Enzymes Involved in the In Vitro Oxidative Metabolism of a Novel Antidepressant, Lu AA21004. Drug Metab Dispos 2012;40:1357-65. [DOI: 10.1124/dmd.112.044610] [Cited by in Crossref: 57] [Cited by in F6Publishing: 36] [Article Influence: 6.3] [Reference Citation Analysis]
125 Pellock SJ, Creekmore BC, Walton WG, Mehta N, Biernat KA, Cesmat AP, Ariyarathna Y, Dunn ZD, Li B, Jin J, James LI, Redinbo MR. Gut Microbial β-Glucuronidase Inhibition via Catalytic Cycle Interception. ACS Cent Sci 2018;4:868-79. [PMID: 30062115 DOI: 10.1021/acscentsci.8b00239] [Cited by in Crossref: 26] [Cited by in F6Publishing: 18] [Article Influence: 8.7] [Reference Citation Analysis]
126 Ivachtchenko AV, Ivanenkov YA. 5HT(6) receptor antagonists: a patent update. Part 1. Sulfonyl derivatives. Expert Opin Ther Pat 2012;22:917-64. [PMID: 22816965 DOI: 10.1517/13543776.2012.709236] [Cited by in Crossref: 13] [Cited by in F6Publishing: 5] [Article Influence: 1.4] [Reference Citation Analysis]
127 Borch jacobsen C, Meldal M, Diness F. Mechanism and Scope of Base-Controlled Catalyst-Free N-Arylation of Amines with Unactivated Fluorobenzenes. Chem Eur J 2017;23:846-51. [DOI: 10.1002/chem.201604098] [Cited by in Crossref: 29] [Cited by in F6Publishing: 11] [Article Influence: 5.8] [Reference Citation Analysis]
128 Rannversson H, Andersen J, Sørensen L, Bang-Andersen B, Park M, Huber T, Sakmar TP, Strømgaard K. Genetically encoded photocrosslinkers locate the high-affinity binding site of antidepressant drugs in the human serotonin transporter. Nat Commun 2016;7:11261. [PMID: 27089947 DOI: 10.1038/ncomms11261] [Cited by in Crossref: 38] [Cited by in F6Publishing: 25] [Article Influence: 7.6] [Reference Citation Analysis]
129 Chakrabarty T, Hadjipavlou G, Lam RW. Cognitive Dysfunction in Major Depressive Disorder: Assessment, Impact, and Management. Focus (Am Psychiatr Publ) 2016;14:194-206. [PMID: 31975803 DOI: 10.1176/appi.focus.20150043] [Cited by in Crossref: 14] [Cited by in F6Publishing: 9] [Article Influence: 2.8] [Reference Citation Analysis]
130 Matsuno K, Nakamura K, Aritomi Y, Nishimura A. Pharmacokinetics, Safety, and Tolerability of Vortioxetine Following Single- and Multiple-Dose Administration in Healthy Japanese Adults. Clin Pharmacol Drug Dev 2018;7:319-31. [PMID: 28941196 DOI: 10.1002/cpdd.381] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
131 Millan MJ, Goodwin GM, Meyer-lindenberg A, Ove Ögren S. Learning from the past and looking to the future: Emerging perspectives for improving the treatment of psychiatric disorders. European Neuropsychopharmacology 2015;25:599-656. [DOI: 10.1016/j.euroneuro.2015.01.016] [Cited by in Crossref: 88] [Cited by in F6Publishing: 64] [Article Influence: 14.7] [Reference Citation Analysis]
132 Berhan A, Barker A. Vortioxetine in the treatment of adult patients with major depressive disorder: a meta-analysis of randomized double-blind controlled trials. BMC Psychiatry 2014;14:276. [PMID: 25260373 DOI: 10.1186/s12888-014-0276-x] [Cited by in Crossref: 25] [Cited by in F6Publishing: 19] [Article Influence: 3.6] [Reference Citation Analysis]
133 Dale E, Pehrson AL, Jeyarajah T, Li Y, Leiser SC, Smagin G, Olsen CK, Sanchez C. Effects of serotonin in the hippocampus: how SSRIs and multimodal antidepressants might regulate pyramidal cell function. CNS Spectr 2016;21:143-61. [PMID: 26346726 DOI: 10.1017/S1092852915000425] [Cited by in Crossref: 65] [Cited by in F6Publishing: 24] [Article Influence: 10.8] [Reference Citation Analysis]
134 Liu X, Sun YX, Zhang CC, Zhang XQ, Zhang Y, Wang T, Ma YN, Wang H, Su YA, Li JT, Si TM. Vortioxetine attenuates the effects of early-life stress on depression-like behaviors and monoamine transporters in female mice. Neuropharmacology 2021;186:108468. [PMID: 33485943 DOI: 10.1016/j.neuropharm.2021.108468] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
135 Miao J, Wang G, Hou J, Areberg J, Zhao Y, Højer AM, Ettrup A. Pharmacokinetics and Safety of Vortioxetine in the Chinese Population. Adv Ther 2019;36:3134-46. [PMID: 31552551 DOI: 10.1007/s12325-019-01092-4] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
136 Juza R, Vlcek P, Mezeiova E, Musilek K, Soukup O, Korabecny J. Recent advances with 5-HT3 modulators for neuropsychiatric and gastrointestinal disorders. Med Res Rev 2020;40:1593-678. [PMID: 32115745 DOI: 10.1002/med.21666] [Cited by in Crossref: 9] [Cited by in F6Publishing: 4] [Article Influence: 9.0] [Reference Citation Analysis]
137 Thase ME, Danchenko N, Brignone M, Florea I, Diamand F, Jacobsen PL, Vieta E. Comparative evaluation of vortioxetine as a switch therapy in patients with major depressive disorder. European Neuropsychopharmacology 2017;27:773-81. [DOI: 10.1016/j.euroneuro.2017.05.009] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
138 Huang LH, Xu HD, Yang ZY, Zheng YF, Liu HM. Synthesis and anticancer activity of novel C6-piperazine substituted purine steroid-nucleosides analogues. Steroids 2014;82:1-6. [PMID: 24378780 DOI: 10.1016/j.steroids.2013.12.004] [Cited by in Crossref: 16] [Cited by in F6Publishing: 11] [Article Influence: 2.0] [Reference Citation Analysis]
139 Perini G, Cotta Ramusino M, Sinforiani E, Bernini S, Petrachi R, Costa A. Cognitive impairment in depression: recent advances and novel treatments. Neuropsychiatr Dis Treat 2019;15:1249-58. [PMID: 31190831 DOI: 10.2147/NDT.S199746] [Cited by in Crossref: 42] [Cited by in F6Publishing: 10] [Article Influence: 21.0] [Reference Citation Analysis]
140 Waller JA, Chen F, Sánchez C. Vortioxetine promotes maturation of dendritic spines in vitro: A comparative study in hippocampal cultures. Neuropharmacology 2016;103:143-54. [PMID: 26702943 DOI: 10.1016/j.neuropharm.2015.12.012] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 2.3] [Reference Citation Analysis]
141 Connolly KR, Thase ME. Vortioxetine: a New Treatment for Major Depressive Disorder. Expert Opinion on Pharmacotherapy 2016;17:421-31. [DOI: 10.1517/14656566.2016.1133588] [Cited by in Crossref: 36] [Cited by in F6Publishing: 15] [Article Influence: 7.2] [Reference Citation Analysis]
142 Staroń J, Bugno R, Hogendorf AS, Bojarski AJ. 5-HT1A receptor ligands and their therapeutic applications: review of new patents. Expert Opinion on Therapeutic Patents 2018;28:679-89. [DOI: 10.1080/13543776.2018.1514011] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 4.3] [Reference Citation Analysis]
143 Boulenger JP, Loft H, Olsen CK. Efficacy and safety of vortioxetine (Lu AA21004), 15 and 20 mg/day: a randomized, double-blind, placebo-controlled, duloxetine-referenced study in the acute treatment of adult patients with major depressive disorder. Int Clin Psychopharmacol. 2014;29:138-149. [PMID: 24257717 DOI: 10.1097/yic.0000000000000018] [Cited by in Crossref: 102] [Cited by in F6Publishing: 28] [Article Influence: 14.6] [Reference Citation Analysis]
144 Faquih AE, Memon RI, Hafeez H, Zeshan M, Naveed S. A Review of Novel Antidepressants: A Guide for Clinicians. Cureus 2019;11:e4185. [PMID: 31106085 DOI: 10.7759/cureus.4185] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 2.5] [Reference Citation Analysis]
145 Sanchez C, Asin KE, Artigas F. Vortioxetine, a novel antidepressant with multimodal activity: Review of preclinical and clinical data. Pharmacology & Therapeutics 2015;145:43-57. [DOI: 10.1016/j.pharmthera.2014.07.001] [Cited by in Crossref: 245] [Cited by in F6Publishing: 164] [Article Influence: 40.8] [Reference Citation Analysis]
146 Leiser SC, Pehrson AL, Robichaud PJ, Sanchez C. Multimodal antidepressant vortioxetine increases frontal cortical oscillations unlike escitalopram and duloxetine--a quantitative EEG study in rats. Br J Pharmacol 2014;171:4255-72. [PMID: 24846338 DOI: 10.1111/bph.12782] [Cited by in Crossref: 40] [Cited by in F6Publishing: 32] [Article Influence: 6.7] [Reference Citation Analysis]
147 Theunissen EL, Street D, Højer A, Vermeeren A, van Oers A, Ramaekers JG. A Randomized Trial on the Acute and Steady-State Effects of a New Antidepressant, Vortioxetine (Lu AA21004), on Actual Driving and Cognition. Clin Pharmacol Ther 2013;93:493-501. [DOI: 10.1038/clpt.2013.39] [Cited by in Crossref: 37] [Cited by in F6Publishing: 23] [Article Influence: 4.6] [Reference Citation Analysis]
148 Alvarez E, Perez V, Artigas F. Pharmacology and clinical potential of vortioxetine in the treatment of major depressive disorder. Neuropsychiatr Dis Treat 2014;10:1297-307. [PMID: 25075188 DOI: 10.2147/NDT.S41387] [Cited by in Crossref: 38] [Cited by in F6Publishing: 11] [Article Influence: 5.4] [Reference Citation Analysis]
149 Fu J, Peng L, Li X. The efficacy and safety of multiple doses of vortioxetine for generalized anxiety disorder: a meta-analysis. Neuropsychiatr Dis Treat 2016;12:951-9. [PMID: 27143896 DOI: 10.2147/NDT.S104050] [Cited by in Crossref: 8] [Cited by in F6Publishing: 3] [Article Influence: 1.6] [Reference Citation Analysis]
150 Guan S, Zou Y, Jia B, Wu L, Yang Z, Yuan F, Zhang L. Pharmacokinetic and metabolic studies of Vortioxetine in rats using ultra high performance liquid chromatography with tandem mass spectrometry. J Sep Sci 2018;41:4469-79. [DOI: 10.1002/jssc.201800607] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 1.7] [Reference Citation Analysis]
151 Malikowska-Racia N, Popik P, Sałat K. Behavioral effects of buspirone in a mouse model of posttraumatic stress disorder. Behav Brain Res 2020;381:112380. [PMID: 31765726 DOI: 10.1016/j.bbr.2019.112380] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
152 Gibb A, Deeks ED. Vortioxetine: First Global Approval. Drugs 2014;74:135-45. [DOI: 10.1007/s40265-013-0161-9] [Cited by in Crossref: 34] [Cited by in F6Publishing: 15] [Article Influence: 4.3] [Reference Citation Analysis]
153 Zhang W, Huang M, Zou Z, Wu Z, Ni S, Kong L, Zheng Y, Wang Y, Pan Y. Redox-active benzimidazolium sulfonamides as cationic thiolating reagents for reductive cross-coupling of organic halides. Chem Sci 2020;12:2509-14. [PMID: 34164018 DOI: 10.1039/d0sc06446g] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
154 Areberg J, Søgaard B, Højer AM. The clinical pharmacokinetics of Lu AA21004 and its major metabolite in healthy young volunteers. Basic Clin Pharmacol Toxicol 2012;111:198-205. [PMID: 22448783 DOI: 10.1111/j.1742-7843.2012.00886.x] [Cited by in Crossref: 9] [Cited by in F6Publishing: 13] [Article Influence: 1.0] [Reference Citation Analysis]
155 Adamo D, Pecoraro G, Coppola N, Calabria E, Aria M, Mignogna M. Vortioxetine versus other antidepressants in the treatment of burning mouth syndrome: An open-label randomized trial. Oral Dis 2021;27:1022-41. [PMID: 32790904 DOI: 10.1111/odi.13602] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
156 Cicco L, Dilauro G, Perna FM, Vitale P, Capriati V. Advances in deep eutectic solvents and water: applications in metal- and biocatalyzed processes, in the synthesis of APIs, and other biologically active compounds. Org Biomol Chem 2021;19:2558-77. [DOI: 10.1039/d0ob02491k] [Cited by in Crossref: 13] [Cited by in F6Publishing: 1] [Article Influence: 13.0] [Reference Citation Analysis]
157 Brivio P, Corsini G, Riva MA, Calabrese F. Chronic vortioxetine treatment improves the responsiveness to an acute stress acting through the ventral hippocampus in a glucocorticoid-dependent way. Pharmacological Research 2019;142:14-21. [DOI: 10.1016/j.phrs.2019.02.006] [Cited by in Crossref: 18] [Cited by in F6Publishing: 14] [Article Influence: 9.0] [Reference Citation Analysis]
158 Citrome L. Vortioxetine for major depressive disorder: a systematic review of the efficacy and safety profile for this newly approved antidepressant - what is the number needed to treat, number needed to harm and likelihood to be helped or harmed? Int J Clin Pract. 2014;68:60-82. [PMID: 24165478 DOI: 10.1111/ijcp.12350] [Cited by in Crossref: 45] [Cited by in F6Publishing: 23] [Article Influence: 5.6] [Reference Citation Analysis]
159 Jacobsen PL, Harper L, Chrones L, Chan S, Mahableshwarkar AR. Safety and tolerability of vortioxetine (15 and 20 mg) in patients with major depressive disorder: results of an open-label, flexible-dose, 52-week extension study. Int Clin Psychopharmacol 2015;30:255-64. [PMID: 26020712 DOI: 10.1097/YIC.0000000000000081] [Cited by in Crossref: 20] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
160 Mahableshwarkar AR, Jacobsen PL, Chen Y, Simon JS. A randomised, double-blind, placebo-controlled, duloxetine-referenced study of the efficacy and tolerability of vortioxetine in the acute treatment of adults with generalised anxiety disorder. Int J Clin Pract 2014;68:49-59. [DOI: 10.1111/ijcp.12328] [Cited by in Crossref: 33] [Cited by in F6Publishing: 19] [Article Influence: 4.1] [Reference Citation Analysis]
161 Xue W, Fu T, Zheng G, Tu G, Zhang Y, Yang F, Tao L, Yao L, Zhu F. Recent Advances and Challenges of the Drugs Acting on Monoamine Transporters. CMC 2020;27:3830-76. [DOI: 10.2174/0929867325666181009123218] [Cited by in Crossref: 13] [Cited by in F6Publishing: 8] [Article Influence: 13.0] [Reference Citation Analysis]
162 Hansen SVF, Ulven T. Pharmacological Tool Compounds for the Free Fatty Acid Receptor 4 (FFA4/GPR120). In: Milligan G, Kimura I, editors. Free Fatty Acid Receptors. Cham: Springer International Publishing; 2017. pp. 33-56. [DOI: 10.1007/164_2016_60] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.6] [Reference Citation Analysis]
163 Lacivita E, Di Pilato P, De Giorgio P, Colabufo NA, Berardi F, Perrone R, Leopoldo M. The therapeutic potential of 5-HT1A receptors: a patent review. Expert Opinion on Therapeutic Patents 2012;22:887-902. [DOI: 10.1517/13543776.2012.703654] [Cited by in Crossref: 26] [Cited by in F6Publishing: 20] [Article Influence: 2.9] [Reference Citation Analysis]
164 Chen G, Lee R, Højer AM, Buchbjerg JK, Serenko M, Zhao Z. Pharmacokinetic drug interactions involving vortioxetine (Lu AA21004), a multimodal antidepressant. Clin Drug Investig 2013;33:727-36. [PMID: 23975654 DOI: 10.1007/s40261-013-0117-6] [Cited by in Crossref: 58] [Cited by in F6Publishing: 31] [Article Influence: 8.3] [Reference Citation Analysis]
165 Sparling BA, Dimauro EF. Progress in the discovery of small molecule modulators of the Cys-loop superfamily receptors. Bioorganic & Medicinal Chemistry Letters 2017;27:3207-18. [DOI: 10.1016/j.bmcl.2017.04.073] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 2.3] [Reference Citation Analysis]
166 Zarkadas E, Zhang H, Cai W, Effantin G, Perot J, Neyton J, Chipot C, Schoehn G, Dehez F, Nury H. The Binding of Palonosetron and Other Antiemetic Drugs to the Serotonin 5-HT3 Receptor. Structure 2020;28:1131-1140.e4. [DOI: 10.1016/j.str.2020.07.004] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
167 Alvarez E, Perez V, Dragheim M, Loft H, Artigas F. A double-blind, randomized, placebo-controlled, active reference study of Lu AA21004 in patients with major depressive disorder. Int J Neuropsychopharmacol. 2012;15:589-600. [PMID: 21767441 DOI: 10.1017/s1461145711001027] [Cited by in Crossref: 135] [Cited by in F6Publishing: 35] [Article Influence: 13.5] [Reference Citation Analysis]
168 Bidzan L, Mahableshwarkar AR, Jacobsen P, Yan M, Sheehan DV. Vortioxetine (Lu AA21004) in generalized anxiety disorder: Results of an 8-week, multinational, randomized, double-blind, placebo-controlled clinical trial. European Neuropsychopharmacology 2012;22:847-57. [DOI: 10.1016/j.euroneuro.2012.07.012] [Cited by in Crossref: 47] [Cited by in F6Publishing: 37] [Article Influence: 5.2] [Reference Citation Analysis]
169 Zugliani MM, Cabo MC, Nardi AE, Perna G, Freire RC. Pharmacological and Neuromodulatory Treatments for Panic Disorder: Clinical Trials from 2010 to 2018. Psychiatry Investig 2019;16:50-8. [PMID: 30696238 DOI: 10.30773/pi.2018.12.21.1] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
170 Król M, Ślifirski G, Kleps J, Ulenberg S, Belka M, Bączek T, Siwek A, Stachowicz K, Szewczyk B, Nowak G, Duszyńska B, Herold F. Synthesis of Novel Pyrido[1,2-c]pyrimidine Derivatives with 6-Fluoro-3-(4-piperidynyl)-1,2-benzisoxazole Moiety as Potential SSRI and 5-HT1A Receptor Ligands. Int J Mol Sci 2021;22:2329. [PMID: 33652672 DOI: 10.3390/ijms22052329] [Reference Citation Analysis]
171 Roberts A, Grafton G, Powell AD, Brock K, Chen C, Xie D, Huang J, Liu S, Cooper AJ, Brady CA, Qureshi O, Stamataki Z, Manning DD, Moore NA, Sargent BJ, Guzzo PR, Barnes NM. CSTI-300 (SMP-100); a Novel 5-HT3 Receptor Partial Agonist with Potential to Treat Patients with Irritable Bowel Syndrome or Carcinoid Syndrome. J Pharmacol Exp Ther 2020;373:122-34. [PMID: 32102919 DOI: 10.1124/jpet.119.261008] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
172 Fernandes RA, Bhowmik A, Yadav SS. Advances in Cu and Ni-catalyzed Chan–Lam-type coupling: synthesis of diarylchalcogenides, Ar 2 –X (X = S, Se, Te). Org Biomol Chem 2020;18:9583-600. [DOI: 10.1039/d0ob02035d] [Cited by in Crossref: 4] [Article Influence: 4.0] [Reference Citation Analysis]
173 Wang Y, Nomikos GG, Karim A, Munsaka M, Serenko M, Liosatos M, Harris S. Effect of Vortioxetine on Cardiac Repolarization in Healthy Adult Male Subjects: Results of a Thorough QT/QTc Study: Clinical Pharmacology in Drug Development. CPDD 2013;2:298-309. [DOI: 10.1002/cpdd.51] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.4] [Reference Citation Analysis]
174 Inoue T, Sasai K, Kitagawa T, Nishimura A, Inada I. Randomized, double-blind, placebo-controlled study to assess the efficacy and safety of vortioxetine in Japanese patients with major depressive disorder. Psychiatry Clin Neurosci 2020;74:140-8. [PMID: 31725942 DOI: 10.1111/pcn.12956] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
175 Saltiel PF, Silvershein DI. Major depressive disorder: mechanism-based prescribing for personalized medicine. Neuropsychiatr Dis Treat 2015;11:875-88. [PMID: 25848287 DOI: 10.2147/NDT.S73261] [Cited by in Crossref: 11] [Cited by in F6Publishing: 23] [Article Influence: 1.8] [Reference Citation Analysis]
176 Shalimova A, Babasieva V, Chubarev VN, Tarasov VV, Schiöth HB, Mwinyi J. Therapy response prediction in major depressive disorder: current and novel genomic markers influencing pharmacokinetics and pharmacodynamics. Pharmacogenomics 2021;22:485-503. [PMID: 34018822 DOI: 10.2217/pgs-2020-0157] [Reference Citation Analysis]
177 Emam AM, Saad MA, Ahmed NA, Zaki HF. Vortioxetine mitigates neuronal damage by restricting PERK/eIF2α/ATF4/CHOP signaling pathway in rats subjected to focal cerebral ischemia-reperfusion. Life Sci 2021;283:119865. [PMID: 34358549 DOI: 10.1016/j.lfs.2021.119865] [Reference Citation Analysis]
178 Prus AJ, Porter JH. The Discriminative Stimulus Properties of Drugs Used to Treat Depression and Anxiety. In: Porter JH, Prus AJ, editors. The Behavioral Neuroscience of Drug Discrimination. Cham: Springer International Publishing; 2018. pp. 213-41. [DOI: 10.1007/7854_2016_27] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
179 Jacobsen PL, Mahableshwarkar AR, Chen Y, Chrones L, Clayton AH. Effect of Vortioxetine vs. Escitalopram on Sexual Functioning in Adults with Well-Treated Major Depressive Disorder Experiencing SSRI-Induced Sexual Dysfunction. J Sex Med 2015;12:2036-48. [PMID: 26331383 DOI: 10.1111/jsm.12980] [Cited by in Crossref: 45] [Cited by in F6Publishing: 21] [Article Influence: 7.5] [Reference Citation Analysis]
180 Burhardt MN, Taaning RH, Skrydstrup T. Pd-Catalyzed Thiocarbonylation with Stoichiometric Carbon Monoxide: Scope and Applications. Org Lett 2013;15:948-51. [DOI: 10.1021/ol400138m] [Cited by in Crossref: 80] [Cited by in F6Publishing: 33] [Article Influence: 10.0] [Reference Citation Analysis]
181 Christensen MC, Loft H, Mcintyre RS. Vortioxetine improves symptomatic and functional outcomes in major depressive disorder: A novel dual outcome measure in depressive disorders. Journal of Affective Disorders 2018;227:787-94. [DOI: 10.1016/j.jad.2017.11.081] [Cited by in Crossref: 18] [Cited by in F6Publishing: 11] [Article Influence: 6.0] [Reference Citation Analysis]
182 Westrich L, Haddjeri N, Dkhissi-benyahya O, Sánchez C. Involvement of 5-HT7 receptors in vortioxetine's modulation of circadian rhythms and episodic memory in rodents. Neuropharmacology 2015;89:382-90. [DOI: 10.1016/j.neuropharm.2014.10.015] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 3.7] [Reference Citation Analysis]
183 Ebrahimzadeh M, El Mansari M, Blier P. Partial inhibition of catecholamine activity and enhanced responsiveness to NMDA after sustained administration of vortioxetine. Neuropharmacology 2018;128:425-32. [DOI: 10.1016/j.neuropharm.2017.10.036] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
184 Pehrson AL, Leiser SC, Gulinello M, Dale E, Li Y, Waller JA, Sanchez C. Treatment of cognitive dysfunction in major depressive disorder—a review of the preclinical evidence for efficacy of selective serotonin reuptake inhibitors, serotonin–norepinephrine reuptake inhibitors and the multimodal-acting antidepressant vortioxetine. European Journal of Pharmacology 2015;753:19-31. [DOI: 10.1016/j.ejphar.2014.07.044] [Cited by in Crossref: 59] [Cited by in F6Publishing: 36] [Article Influence: 9.8] [Reference Citation Analysis]
185 Dale E, Zhang H, Leiser SC, Xiao Y, Lu D, Yang CR, Plath N, Sanchez C. Vortioxetine disinhibits pyramidal cell function and enhances synaptic plasticity in the rat hippocampus. J Psychopharmacol 2014;28:891-902. [PMID: 25122043 DOI: 10.1177/0269881114543719] [Cited by in Crossref: 60] [Cited by in F6Publishing: 46] [Article Influence: 8.6] [Reference Citation Analysis]
186 Papakostas GI, Nielsen RZ, Dragheim M, Tonnoir B. Efficacy and tolerability of vortioxetine versus agomelatine, categorized by previous treatment, in patients with major depressive disorder switched after an inadequate response. Journal of Psychiatric Research 2018;101:72-9. [DOI: 10.1016/j.jpsychires.2018.02.017] [Cited by in Crossref: 11] [Cited by in F6Publishing: 5] [Article Influence: 3.7] [Reference Citation Analysis]
187 Mahableshwarkar AR, Jacobsen PL, Serenko M, Chen Y. A randomized, double-blind, fixed-dose study comparing the efficacy and tolerability of vortioxetine 2.5 and 10 mg in acute treatment of adults with generalized anxiety disorder: EFFICACY AND TOLERABILITY OF TWO VORTIOXETINE DOSES IN ACUTE GAD. Hum Psychopharmacol Clin Exp 2014;29:64-72. [DOI: 10.1002/hup.2371] [Cited by in Crossref: 29] [Cited by in F6Publishing: 16] [Article Influence: 4.1] [Reference Citation Analysis]
188 Riga MS, Teruel-martí V, Sánchez C, Celada P, Artigas F. Subchronic vortioxetine treatment –but not escitalopram– enhances pyramidal neuron activity in the rat prefrontal cortex. Neuropharmacology 2017;113:148-55. [DOI: 10.1016/j.neuropharm.2016.09.024] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 4.3] [Reference Citation Analysis]
189 Baldwin DS, Florea I, Jacobsen PL, Zhong W, Nomikos GG. A meta-analysis of the efficacy of vortioxetine in patients with major depressive disorder (MDD) and high levels of anxiety symptoms. Journal of Affective Disorders 2016;206:140-50. [DOI: 10.1016/j.jad.2016.07.015] [Cited by in Crossref: 33] [Cited by in F6Publishing: 20] [Article Influence: 6.6] [Reference Citation Analysis]
190 Grady MM, Stahl SM. Novel agents in development for the treatment of depression. CNS Spectr 2013;18:34-41. [DOI: 10.1017/s1092852913000758] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
191 Lacivita E, Niso M, Hansen HD, Di Pilato P, Herth MM, Lehel S, Ettrup A, Montenegro L, Perrone R, Berardi F, Colabufo NA, Leopoldo M, Knudsen GM. Design, synthesis, radiolabeling and in vivo evaluation of potential positron emission tomography (PET) radioligands for brain imaging of the 5-HT7 receptor. Bioorganic & Medicinal Chemistry 2014;22:1736-50. [DOI: 10.1016/j.bmc.2014.01.016] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 2.1] [Reference Citation Analysis]
192 Lv GB, Wang TT, Zhu HL, Wang HK, Sun W, Zhao LF. Vortioxetine induces apoptosis and autophagy of gastric cancer AGS cells via the PI3K/AKT pathway. FEBS Open Bio 2020;10:2157-65. [PMID: 32750222 DOI: 10.1002/2211-5463.12944] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
193 Findling RL, Robb AS, DelBello MP, Huss M, McNamara NK, Sarkis EH, Scheffer RE, Poulsen LH, Chen G, Lemming OM, Auby P. A 6-Month Open-Label Extension Study of Vortioxetine in Pediatric Patients with Depressive or Anxiety Disorders. J Child Adolesc Psychopharmacol 2018;28:47-54. [PMID: 29035574 DOI: 10.1089/cap.2017.0047] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
194 Inoue T, Nishimura A, Sasai K, Kitagawa T. Randomized, 8-week, double-blind, placebo-controlled trial of vortioxetine in Japanese adults with major depressive disorder, followed by a 52-week open-label extension trial: Vortioxetine in Japanese MDD patients. Psychiatry Clin Neurosci 2018;72:103-15. [DOI: 10.1111/pcn.12623] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
195 Zajdel P, Kurczab R, Grychowska K, Satała G, Pawłowski M, Bojarski AJ. The multiobjective based design, synthesis and evaluation of the arylsulfonamide/amide derivatives of aryloxyethyl- and arylthioethyl- piperidines and pyrrolidines as a novel class of potent 5-HT7 receptor antagonists. European Journal of Medicinal Chemistry 2012;56:348-60. [DOI: 10.1016/j.ejmech.2012.07.043] [Cited by in Crossref: 33] [Cited by in F6Publishing: 20] [Article Influence: 3.7] [Reference Citation Analysis]